ALPHA TAU MEDICAL LTD
DRTSNASDAQTrading Snapshot
- Day Range
- $13.96 – $14.26
- 52-Week Range
- $3.00 – $14.40
- Volume
- $3.37B
- Avg Volume
- $4.43B
- Shares Outstanding
- 90.3M
- Next Earnings
- Oct 14, 2026
Fundamentals Snapshot
- Annual Revenue
- $161M
- Last Q Revenue
- $42M
- P/E Ratio
- -21.0
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.63
- Dividend Yield
- 0.00%
Why Investors Own DRTS
- ✓High-growth profile — revenue up +13.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 67% gross margin and 17% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ALPHA TAU MEDICAL LTD
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
HC Wainwright & Co. Maintains Buy on Alpha Tau Medical, Raises Price Target to $16
HC Wainwright & Co. analyst Yi Chen maintains Alpha Tau Medical (NASDAQ:DRTS) with a Buy and raises the price target from $15 to $16.
Alpha Tau Medical Q2 EPS $(0.50) Misses $(0.14) Estimate
Alpha Tau Medical (NASDAQ:DRTS) reported quarterly losses of $(0.50) per share which missed the analyst consensus estimate of $(0.14) by 257.14 percent. This is a 284.62 percent decrease over losses of $(0.13) per share
HC Wainwright & Co. Reiterates Buy on Alpha Tau Medical, Maintains $15 Price Target
HC Wainwright & Co. analyst Yi Chen reiterates Alpha Tau Medical (NASDAQ:DRTS) with a Buy and maintains $15 price target.
Alpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
- Podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer to report results from a study of Alpha DaRT® in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced or metastatic head and neck squamous cell carcinoma (HNSCC) - - Among all nine evaluable patients, the combination produced a systemic objective response rate (ORR) of 100%, including four complete responses and five partial responses, compared
Alpha Tau Medical Announces Positive Data In Head And Neck Cancer Treatment Study, Hitting 100% Objective Response Rate Across Nine Evaluable Patients
Response RateAmong evaluable patients, treatment with Alpha DaRT plus pembrolizumab produced an objective response rate (i.e., systemic complete response plus partial response) of 100%, including four complete responses
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Jasper Therapeutics (NASDAQ:JSPR) stock moved upwards by 19.2% to $0.92 during Friday's regular session. The company's market cap stands at $21.6 million. Kalaris Therapeutics (NASDAQ:KLRS) shares